News archive

Researchers at the Swiss Federal Institute of Technology Zurich, led by Professor Andreas Hierlemann, have developed a microfluidic 3D blood-brain barrier model that can be used to better investigate, for example, therapies against brain tumors.

The European Directorate for the Quality of Medicines (EDQM) has published 59 amended texts in the European Pharmacopoeia (Ph. Eur.) concerning the rabbit pyrogenicity test for public consultation. The goal is to replace the rabbit test with an in vitro alternative.

A team of researchers from the Helmholtz Institute for Pharmaceutical Research at Saarland University (HIPS), led by Prof. Claus-Michael Lehr has developed a new human lung cell line for drug testing and disease model development.

The 3Rs Centre Utrecht launches a campaign on social media, aimed at researchers who work with Fetal Calf Serum (FCS).

On January 20, the European Parliament's Committee on Budgetary Control introduced a draft decision on the discharge of the budget of the European Medicines Agency (EMA). Therein, the authors point out that priority must be given to the replacement of animal testing when developing medicines.

The PETA Science Consortium International e.V. has announced a Travel Award for participation in the 12th World Congress on Alternatives and Animal Use in Life Sciences. The congress will be held August 27-31, 2023, in Canada near Niagara Falls.

A new BMBF funding directive aims to advance the study of the natural course of rare diseases.

The OECD Working Group of the National Coordinator for the Test Guidelines Programme (WNT), supported by the OECD's Chemicals and Biotechnology Committee, is calling for the urgent mobilization of national and regional resources to demonstrate the reproducibility and reliability of new animal welfare-free methods, called NAMs (New Approach Methodologies).

The PETA Science Consortium International and the Swiss company Epithelix have announced a prize. up for grabs is a three-dimensional human respiratory tissue worth $15,000 for research into harmful processes caused by inhalation of toxic substances.

In order to optimize the production of 3D cell culture systems such as organoids from patient stem cells,  scientists at the Max Delbrück Center want to automate this process. The goal is to be able to offer an automated, reliable process for high-throughput experiments that is also attractive to the industry.